Podiatrist Loses Drug Rights After Hiding License Suspension Lie
Published Date: 6/13/2025
Notice
Summary
James F. Brown, a podiatrist from Los Angeles, lost his DEA registration because he lied about his suspended medical license and can’t legally handle controlled substances in California. Since he didn’t ask for a hearing, the DEA revoked his registration by default. This means he can no longer prescribe or handle certain drugs, effective immediately.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Revoked Effective July 14, 2025
The DEA revoked Certificate of Registration No. BB7959731 issued to James F. Brown, D.P.M., and the revocation is effective July 14, 2025. As a result, he can no longer prescribe, order, dispense, administer, or possess controlled substances under his DEA registration in California.
Pending Renewal and New Registration Applications Denied
The Order denies any pending applications by James F. Brown to renew or modify DEA registration No. BB7959731 and denies any other pending application of his for additional registration in California. This denial is effective as part of the same Order effective July 14, 2025.
Material Falsification Finding on DEA Renewal
The Agency found that on his June 20, 2023 DEA renewal application, James F. Brown answered "N" to Liability Question 3 despite a prior suspension and related actions by the Podiatric Medical Board of California. The Agency concluded this was a clear, unequivocal, and convincing material falsification and used that finding as a basis for revocation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-10741, TriplePoint Venture Growth BDC Corp., et al.
TriplePoint Venture Growth BDC Corp. and its related companies want permission to team up and invest together in the same businesses, which usually isn’t allowed. This change could help them share opportunities and grow investments more smoothly. If you want to speak up, you have until July 7, 2025, to ask for a hearing before the SEC decides.
Next: 2025-10743, Silicon Metal From Angola, Australia, Laos, Norway, and Thailand
The U.S. is checking if silicon metal imports from Angola, Australia, Laos, Norway, and Thailand are hurting American businesses by being sold too cheaply or getting unfair government help. The investigation is moving to the final phase, which could lead to new rules or tariffs to protect U.S. companies. If you’re involved in this trade, keep an eye out for updates soon that might affect prices and import rules.